Chief Legal Officer and General Counsel · Amylyx Pharmaceuticals, Inc. (AMLX)

Gina Mazzariello

A named executive officer of Amylyx Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,298,996

Salary $478,400Stock awards $805,798

FY2023: $3,013,676

4th of 4 named executive officers at Amylyx Pharmaceuticals by FY2024 total.

4 named officers on file for Amylyx Pharmaceuticals, FY2024

Gina Mazzariello’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • AMLX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Amylyx Pharmaceuticals’s whole pay program stands against its peers

  • Amylyx Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AMLX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Gina Mazzariello’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Gina Mazzariello compensation by year

Amylyx Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Amylyx Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$342,593$460,000$478,400
Bonus$250,000$0$0
Stock awards$1,229,180$588,123$805,798
Option awards$4,089,540$1,736,288$777,704
Non-equity incentive$193,085$217,765$219,844
Pension and deferred compensation$0$0$0
All other$9,150$11,500$17,250
Total$6,113,548$3,013,676$2,298,996

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amylyx Pharmaceuticals, Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-057665, and prior-year filings.

How this page was built: the Amylyx Pharmaceuticals, Inc. filed document, accession 0000950170-25-057665. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

$6.1M
$3.0M
$2.3M
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU53,707$203,012—
RSU36,667$138,601—
RSU20,500$77,490—
RSU13,750$51,975—
Option45,044—$32.08
Option55,000—$17.56
Option110,000—$2.01
Option53,084—$28.24

Per the Outstanding Equity Awards at Fiscal Year-End table in Amylyx Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

14 Form 4 lines since the FY2024 proxy (filed April 24, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-10Sale—9,525$32.46190,849
2026-09-10Sale—11$33.34190,838
2026-08-18Grant or award—21,284$0.00200,374
2026-07-10Sale10b5-115,000$17.61179,090
2026-07-09Sale10b5-115,000$18.32194,090
2026-03-05Grant or award derivative—111,990$0.00111,990
2026-03-05Grant or award—74,660$0.00209,090
2026-03-02Sale—6,844$14.52134,430

The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Amylyx Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Justin KleeCo-Chief Executive Officer and Director$6,496,255
Joshua CohenCo-Chief Executive Officer and Director$6,496,255
James FratesChief Financial Officer$2,540,353
Gina Mazzariello · this pageChief Legal Officer and General Counsel$2,298,996

The full Amylyx Pharmaceuticals compensation record

free company brief

This page is one person within Amylyx Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Amylyx Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amylyx Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gina Mazzariello's compensation dossier · One-time report. No refunds.